Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM)

Price 218.00p on 14-02-2025 at 17:30:00
Change 6.00p 2.83%
Buy 221.00p
Sell 217.00p
Buy / Sell HCM Shares
Last Trade: Sell 5,674.00 at 218.00p
Day's Volume: 27,200
Last Close: 218.00p
Open: 217.00p
ISIN: KYG4672N1198
Day's Range 210.00p - 222.00p
52wk Range: 206.00p - 353.00p
Market Capitalisation: £1,863m
VWAP: 218.75825p
Shares in Issue: 855m

Recent Trades History Hutchmed (HCM)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 5,674 218.00p Uncrossing Trade
16:35:05 - 14-Feb-25
Buy* 104 220.00p Automatic Execution
16:19:30 - 14-Feb-25
Buy* 5,287 221.9385p Ordinary
16:16:10 - 14-Feb-25
Buy* 11 222.00p Automatic Execution
16:04:52 - 14-Feb-25
Buy* 8 222.00p Automatic Execution
16:04:52 - 14-Feb-25
Buy* 2,250 221.959p Ordinary
16:00:27 - 14-Feb-25
Buy* 1,355 220.496p Ordinary
15:44:31 - 14-Feb-25
Buy* 209 221.00p Automatic Execution
15:39:28 - 14-Feb-25
Sell* 2,284 219.1665p Ordinary
15:22:37 - 14-Feb-25
Buy* 9 222.00p Automatic Execution
15:12:23 - 14-Feb-25

Share Price History for Hutchmed

Time period:
to
Date Open High Low Close Volume

Share News for Hutchmed

IN BRIEF: Hutchmed lung cancer treatment Orpathys approved in China

14th Jan 2025 12:07

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Says its lung cancer treatment Orpathys has received full approval in China for adult patients. It has been developed in collaboration with AstraZeneca PLC, with Hutchmed leading in China and AZ leading outside of China. The drug was approved by the China National Medical Products Administration for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer. The approval was based on data from the confirmatory phase 3B clinical trial. Read More

LONDON MARKET OPEN: Stocks green but "policy uncertainties mount"

14th Jan 2025 09:02

(Alliance News) - Stock prices in London opened higher on Tuesday ahead of important US producer price inflation data due this afternoon. Read More

Hutchmed China disposes of 45% stake in Shanghai joint venture

2nd Jan 2025 10:46

(Alliance News) - Hutchmed (China) Ltd on Thursday said it has agreed to divest a 45% stake in Shanghai Hutchison Pharmaceuticals Ltd to GP Health Service Capital Co Ltd and Shanghai Pharmaceuticals Holding Co Ltd, for a total of around USD608 million. Read More

LONDON BRIEFING: Chrysalis settles claims with Revolution Beauty

2nd Jan 2025 07:48

(Alliance News) - London's FTSE 100 is set to open the year in the green, with a series of manufacturing purchasing managers' index readings the first hurdle for equities in 2025. Read More

IN BRIEF: Hutchmed to get Takeda milestone payment

13th Dec 2024 10:04

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Is to receive a USD10 million milestone payment from partner Takeda Pharmaceutical Co Ltd. Takeda receives a national reimbursement recommendation for the Fruzaqla cancer treatment in Spain this month. It is the first national reimbursement recommendation in Europe for the drug. "We are delighted for both our partner, Takeda, and patients in Spain who will now be able to receive reimbursement for this innovative treatment. This is an important step forward in improving patient access across Europe more broadly," Hutchmed Chief Executive Officer Weiguo Su says. "It also underscores our ongoing collaboration with Takeda and reinforces our shared commitment to addressing the needs of patients with metastatic colorectal cancer." Read More

FTSE 100 Latest
Value8,732.46
Change-32.26

Login to your account

Forgot Password?

Not Registered